Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem (Q87338395)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Qingen Ke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Mohammed A Samad

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Soochan Bae

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

David J Chaplin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Peter M Kang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

16 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

73-79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Combretastatin-induced hypertension and the consequences for its combination with other therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Response of caspase-independent apoptotic factors to high salt diet-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Pharmacokinetics of diltiazem after intravenous and oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

A review on various targeted anticancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Medicinal chemistry of combretastatin A4: present and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Molecularly targeted oncology therapeutics and prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Endothelial function as a determinant of vascular function and structure: a new therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

Regulation of endothelin-1 gene expression by cell shape and the microfilament network in vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.05.004

10.1016/J.VPH.2015.05.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989107%20AND%20SRC:MED&resulttype=core&format=json